GlassScriptPhysician profile
Victoria Chapman
NPI 1073355251
$3,682.99
in general payments reported to CMS, 2019-2025
36 companies · $2,444 in 2025
The $2,444 reported for 2025 was more than what 95% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,239 · 2025: $2,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.05 |
| Education | $282.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $579.88 | 2024-2025 | Erleada, Darzalex, Talvey |
| Incyte Corporation | $380.35 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $245.39 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $241.82 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $236.83 | 2024-2025 | Imfinzi, Lynparza, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $168.51 | 2024-2025 | Fruzaqla, Ninlaro, Iclusig |
| Genentech USA, INC. | $150.34 | 2025 | Polivy, Tecentriq, Itovebi |
| Regeneron Healthcare Solutions, INC. | $121.60 | 2024-2025 | Libtayo, Lynozyfic |
| E.R. Squibb & Sons, L.L.C. | $106.99 | 2025 | Opdivo |
| Merck Sharp & Dohme LLC | $106.19 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $102.92 | 2024-2025 | |
| Stemline Therapeutics INC. | $88.60 | 2024-2025 | Orserdu |
| Emd Serono, INC. | $83.43 | 2024-2025 | |
| Glaxosmithkline, LLC. | $82.46 | 2024-2025 | Zejula, Jemperli |
| Pharmacosmos Therapeutics INC. | $80.35 | 2025 | Monoferric |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $77.76 | 2024-2025 | Besremi |
| Celgene Corporation | $77.12 | 2025 | Reblozyl, Breyanzi |
| Daiichi Sankyo INC. | $76.17 | 2024-2025 | Enhertu |
| Beigene USA, INC. | $69.80 | 2024-2025 | Brukinsa |
| Astellas Pharma US INC | $68.69 | 2025 | Vyloy, Padcev |
| Aveo Pharmaceuticals, INC. | $68.15 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $61.71 | 2024-2025 | Clonoseq |
| Genmab U.S., INC. | $59.67 | 2024 | Tivdak |
| Tempus Ai, INC | $49.22 | 2025 | Xt Cdx |
| Pfizer INC. | $48.99 | 2024-2025 | |
| Blueprint Medicines Corporation | $37.01 | 2024 | Ayvakit |
| Genzyme Corporation | $34.60 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $32.49 | 2024 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $23.21 | 2025 | Danziten |
| Geron Corporation | $19.57 | 2025 | Rytelo |
| Verity Pharmaceuticals INC. | $19.33 | 2025 | Trelstar |
| Exelixis INC. | $18.82 | 2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $16.56 | 2025 | Romvimza, Qinlock |
| Karyopharm Therapeutics INC. | $16.52 | 2024 | Xpovio |
| Pharmaand Gmbh | $15.97 | 2025 | Rubraca |
| Tolmar, INC. | $15.97 | 2025 | Eligard, Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.